It seems likely, however, that following careful 'hypothesis driven' validation studies and clinical trials, expression profiling will be applied in the future to identify patient-specific disease profiles and provide rationale for individualised treatment.
This procedure resulted in a trial-by-trial expression of Shannon surprise which we included as parametric modulator of the outcome for each trial.
In this trial, EGFR expression was also evaluated by immunohistochemistry, and a correlation between EGFR expression and longer progression-free and overall survival was suggested (P=0.008 and P=0.08, respectively).
If confirmed in a large independent trial, the expression of Maspin should help to discriminate IHCCA patients with a better prognosis.
If confirmed in a large independent trial, the expression of HSP27 should help to discriminate IHCCA patients with a better prognosis.
In this trial, the expression of EGFR family members was also examined by IHC in archival tumours and there was no association of EGFR family member expression level and clinical outcome.
In order to improve the efficacy of targeted therapy trials, the expression profiles of several molecular markers that are potential candidates for targeted therapy were analyzed in patients with progressive castration-resistant prostate cancer.
Other ongoing clinical trials include expression of mutant AGT proteins that confer resistance to O6-BG in bone marrow stem cells, in an effort to reduce the potential enhanced toxicity and mutagenicity of alkylating agents in the bone marrow.
As multiple agents targeting the IGF-IR are currently in early clinical trials, IRS expression should be considered as a potential biomarker for IGF-IR responsiveness.
